TherapeuticsMD, Inc. (TXMD) financial statements (2021 and earlier)

Company profile

Business Address 951 YAMATO ROAD, SUITE 220
BOCA RATON, FL 33431
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments161162127132655154
Cash and cash equivalents161162127132655154
Receivables241145322
Inventory, net of allowances, customer advances and progress billings12311111
Inventory12311111
Prepaid expense7411110
Deferred costs     00
Other current assets      2
Other undisclosed current assets575111(1)
Total current assets:208187140139715659
Noncurrent Assets
Property, plant and equipment30   00
Intangible assets, net (including goodwill) 432211
Intangible assets, net (excluding goodwill) 432211
Prepaid expense    11 
Deposits noncurrent assets 000000
Other noncurrent assets55      
Other undisclosed noncurrent assets 20   (0)2
Total noncurrent assets:582533333
Other undisclosed assets 001000
TOTAL ASSETS:266212143142745962
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:19341113600
Accounts payable192347362
Accrued liabilities 31100 
Employee-related liabilities 85431 
Other undisclosed accounts payable and accrued liabilities     (8)(2)
Other liabilities341898844
Other undisclosed current liabilities (11)(7)(5)(3)73
Total current liabilities:5341131511117
Noncurrent Liabilities
Long-term debt and lease obligation20473     
Long-term debt, excluding current maturities19573     
Operating lease, liability9
Total noncurrent liabilities:20473     
Total liabilities:257114131511117
Stockholders' equity
Stockholders' equity attributable to parent, including:998130127634855
Common stock0000000
Additional paid in capital704617516437283183135
Accumulated deficit(695)(519)(387)(310)(220)(135)(81)
Warrants and rights outstanding     1414
Other undisclosed stockholders' equity attributable to parent     (14)(14)
Total stockholders' equity:998130127634855
TOTAL LIABILITIES AND EQUITY:266212143142745962

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues5016171920159
Revenue, net171920159
Cost of revenue
(Cost of Goods and Services Sold)
(6)(3)(3)(4)(5)(4)(2)
Gross profit:4313141516117
Operating expenses(195)(144)(92)(105)(101)(65)(33)
Operating loss:(151)(130)(78)(90)(85)(54)(26)
Nonoperating income (expense)(25)(2)100(0)(3)
Investment income, nonoperating  00000
Other nonoperating income3210000
Interest and debt expense(10)(0)   (1)(1)
Loss from continuing operations before equity method investments, income taxes:(186)(133)(77)(90)(85)(55)(30)
Other undisclosed income from continuing operations before income taxes100   11
Net loss available to common stockholders, diluted:(176)(133)(77)(90)(85)(54)(28)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(176)(133)(77)(90)(85)(54)(28)
Comprehensive loss, net of tax, attributable to parent:(176)(133)(77)(90)(85)(54)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: